Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $56.50 Average Target Price from Analysts

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been given an average rating of “Moderate Buy” by the seven analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $56.50.

A number of brokerages have commented on ESTA. Wall Street Zen cut Establishment Labs from a “hold” rating to a “sell” rating in a research note on Saturday. Canaccord Genuity Group began coverage on Establishment Labs in a research report on Wednesday, August 20th. They set a “buy” rating and a $60.00 target price on the stock. Mizuho lifted their target price on Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Establishment Labs in a research report on Wednesday. Finally, Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a research report on Tuesday.

Establishment Labs Price Performance

Shares of ESTA opened at $38.94 on Monday. Establishment Labs has a 1 year low of $26.56 and a 1 year high of $50.85. The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -12.77 and a beta of 0.85. The business has a 50-day moving average of $39.61 and a 200-day moving average of $38.04.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The company had revenue of $51.30 million for the quarter, compared to the consensus estimate of $50.80 million. During the same quarter last year, the business earned ($0.62) earnings per share. Establishment Labs’s revenue was up 16.1% compared to the same quarter last year. Establishment Labs has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Establishment Labs will post -2.41 earnings per share for the current year.

Institutional Trading of Establishment Labs

A number of hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC lifted its holdings in Establishment Labs by 7.2% during the first quarter. Nantahala Capital Management LLC now owns 1,774,044 shares of the company’s stock worth $72,390,000 after acquiring an additional 119,574 shares during the period. Tyro Capital Management LLC lifted its holdings in Establishment Labs by 0.3% during the second quarter. Tyro Capital Management LLC now owns 1,066,721 shares of the company’s stock worth $45,560,000 after acquiring an additional 2,835 shares during the period. Bamco Inc. NY lifted its holdings in Establishment Labs by 21.5% during the second quarter. Bamco Inc. NY now owns 907,537 shares of the company’s stock worth $38,761,000 after acquiring an additional 160,755 shares during the period. William Blair Investment Management LLC lifted its holdings in Establishment Labs by 2.1% during the second quarter. William Blair Investment Management LLC now owns 865,244 shares of the company’s stock worth $36,955,000 after acquiring an additional 17,855 shares during the period. Finally, Rice Hall James & Associates LLC lifted its holdings in Establishment Labs by 7.4% during the first quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company’s stock worth $33,763,000 after acquiring an additional 56,756 shares during the period. 72.91% of the stock is currently owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.